{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:10:52Z","timestamp":1760836252679,"version":"build-2065373602"},"reference-count":42,"publisher":"Elsevier BV","issue":"19","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic &amp; Medicinal Chemistry"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.bmc.2017.08.020","type":"journal-article","created":{"date-parts":[[2017,8,12]],"date-time":"2017-08-12T09:00:43Z","timestamp":1502528443000},"page":"5068-5076","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Anticancer potential of aminomethylidene-diazinanes I. Synthesis of arylaminomethylidene of diazinetriones and its cytotoxic effects tested in glioblastoma cells"],"prefix":"10.1016","volume":"25","author":[{"given":"Nichole A.","family":"Pianovich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathew","family":"Dean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Lassak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Reiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Branko S.","family":"Jursic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2006","series-title":"Russell & Rubinstein's Pathology of Tumors of The Nervous System","author":"McLendon","key":"10.1016\/j.bmc.2017.08.020_b0005"},{"key":"10.1016\/j.bmc.2017.08.020_b0010","doi-asserted-by":"crossref","first-page":"6242","DOI":"10.1073\/pnas.97.12.6242","volume":"97","author":"Holland","year":"2000","journal-title":"Proc Natl Acad Sci"},{"year":"2005","series-title":"Russell & Rubinstein's Pathology of Tumors of the Nervous System","key":"10.1016\/j.bmc.2017.08.020_b0015"},{"key":"10.1016\/j.bmc.2017.08.020_b0020","first-page":"181190","article-title":"Five-year follow-up results for patients diagnosed with anaplastic astrocytoma and effectiveness of concomitant therapy with temozolomide for recurrent anaplastic astrocytoma","volume":"7","author":"Sarica","year":"2012","journal-title":"Asian J Neurosurg"},{"key":"10.1016\/j.bmc.2017.08.020_b0025","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2174\/1874467211205010102","article-title":"Temozolomide: mechanism of action, repair and resistance","volume":"5","author":"Zhang","year":"2012","journal-title":"Curr Mol Pharmacol"},{"key":"10.1016\/j.bmc.2017.08.020_b0030","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2017.08.020_b0035","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF02989644","article-title":"Phase II trial of merbarone in patients with malignant brain tumors","volume":"14","author":"Malik","year":"1997","journal-title":"Med Oncol"},{"key":"10.1016\/j.bmc.2017.08.020_b0040","doi-asserted-by":"crossref","first-page":"17643","DOI":"10.1074\/jbc.273.28.17643","article-title":"Merbarone inhibits the catalytic activity of human topoisomerase ii\u03b1 by blocking DNA cleavage","volume":"273","author":"Fortune","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2017.08.020_b0045","series-title":"Frontiers in Anti-Cancer Drug Discovery","volume":"Vol. 3","author":"Atta-ur-Rahman","year":"2014"},{"key":"10.1016\/j.bmc.2017.08.020_b0050","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/BF00203538","article-title":"Merbarone: an antitumor agent entering clinical trials","volume":"5","author":"Glover","year":"1987","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.bmc.2017.08.020_b0055","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/(SICI)1097-0142(20000201)88:3<637::AID-CNCR22>3.0.CO;2-Y","volume":"88","author":"Doolittle","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.bmc.2017.08.020_b0060","series-title":"Brain Edema XII","article-title":"Quantitative Analysis of Hyperosmotic and Hypothermic Blood-Brain Barrier Opening","volume":"Vol. 86","author":"Ikeda","year":"2003"},{"key":"10.1016\/j.bmc.2017.08.020_b0065","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/107327480401100304","article-title":"Modulation of brain tumor capillaries for enhanced drug delivery selectively to brain tumor","volume":"11","author":"Black","year":"2004","journal-title":"Cancer Control"},{"key":"10.1016\/j.bmc.2017.08.020_b0070","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1158\/1078-0432.CCR-07-1826","volume":"14","author":"Yin","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmc.2017.08.020_b0075","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3747\/co.2007.147","article-title":"Gliadel wafers in the treatment of malignant glioma: a systematic review","volume":"14","author":"Perry","year":"2007","journal-title":"Current oncology."},{"key":"10.1016\/j.bmc.2017.08.020_b0080","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jconrel.2016.04.006","article-title":"Distribution of polymer nanoparticles by convection-enhanced delivery to brain tumors","volume":"232","author":"Saucier-Sawyer","year":"2016","journal-title":"J Controlled Release"},{"key":"10.1016\/j.bmc.2017.08.020_b0085","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1517\/13543780903052764","article-title":"Glioblastoma multiforme: a review of where we have been and where we are going","volume":"18","author":"Adamson","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.bmc.2017.08.020_b0090","doi-asserted-by":"crossref","first-page":"6183","DOI":"10.1016\/j.bmc.2016.09.074","article-title":"Synthesis of N-aryl and Narylcarbamoylamino derivatives of 1,3-diazinane-5-carboxamide and their activity against glioblastoma LN-229 cell line","volume":"25","author":"Hron","year":"2016","journal-title":"Bioor. Med Chem."},{"key":"10.1016\/j.bmc.2017.08.020_b0095","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/jhet.5570380318","article-title":"A simple method for Knoevenagel condensation of a, b-conjugated and aromatic aldehydes with barbituric acid","volume":"38","author":"Jursic","year":"2001","journal-title":"J. Het. Chem."},{"key":"10.1016\/j.bmc.2017.08.020_b0100","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.tetlet.2014.01.046","article-title":"Ligand free open air copper (II) mediated aryl formilation and amination of aryl halides","volume":"55","author":"Komati","year":"2014","journal-title":"Tetrahedron Lett"},{"key":"10.1016\/j.bmc.2017.08.020_h0105","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1007\/s11095-010-0303-7","article-title":"Lipophilicity and its relationship with passive drug permeation","volume":"28","author":"Liu","year":"2011","journal-title":"Pharm Res"},{"key":"10.1016\/j.bmc.2017.08.020_h0110","first-page":"301","article-title":"Lipophilicity parameters and biological activity in a series of compounds with potential cardiovascular applications","volume":"77","author":"Pop","year":"2004","journal-title":"Croat Chem Acta"},{"key":"10.1016\/j.bmc.2017.08.020_b0110","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1602\/neurorx.2.4.541","article-title":"Medicinal Chemical properties of successful central nervous system drugs","volume":"2","author":"Pajouhesh","year":"2005","journal-title":"NeuroRx"},{"key":"10.1016\/j.bmc.2017.08.020_h0120","doi-asserted-by":"crossref","first-page":"7559","DOI":"10.1021\/jm060642i","article-title":"Structure-brain exposure relationship","volume":"49","author":"Hitchcock","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2017.08.020_h0125","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1504\/IJCBDD.2013.052195","article-title":"Analysing molecular polarity surface descriptors to predict blood-brain permeation","volume":"6","author":"Shityakov","year":"2013","journal-title":"Int J Comp Biol Drug Des"},{"key":"10.1016\/j.bmc.2017.08.020_b0120","first-page":"231","article-title":"How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion","volume":"5","author":"Kell","year":"2014","journal-title":"Front Pharm Drug Met Transp"},{"key":"10.1016\/j.bmc.2017.08.020_b0125","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1021\/mp400713v","article-title":"Passive lipoidal diffusion and carrier-mediated cell uptake are both important mechanisms of membrane permeation in drug disposition","volume":"11","author":"Smith","year":"2014","journal-title":"Mol Pharm"},{"key":"10.1016\/j.bmc.2017.08.020_h0140","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1614\/WT-04-001R5","article-title":"Increasing and decreasing pH to enhance the biological activity of nicosulfuron","volume":"19","author":"Green","year":"2005","journal-title":"Weed Technol"},{"key":"10.1016\/j.bmc.2017.08.020_h0145","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3390\/ijms17030388","article-title":"A comparative study of molecular structure, pKa, lipophilicity, solubility, absorption and polar surface area of some antiplatelet drugs","volume":"17","author":"Remko","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2017.08.020_b0135","doi-asserted-by":"crossref","first-page":"4443","DOI":"10.1021\/jp068423w","article-title":"Fast approaches for molecular polarizability calculations","volume":"111","author":"Wang","year":"2007","journal-title":"J Phys Chem A"},{"key":"10.1016\/j.bmc.2017.08.020_b0140","first-page":"750","article-title":"Prediction of solubility of practically insoluble drugs in water\/ethanol solvents using non-empirical methods","volume":"3","author":"Fujisawa","year":"2011","journal-title":"J Chem Pharm Res"},{"key":"10.1016\/j.bmc.2017.08.020_h0160","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nrd3701","article-title":"Finding the Sweet Spot: the Role of Nature and Nurture in Medicinal Chemistry","volume":"11","author":"Hann","year":"2012","journal-title":"Nat Rev Drug Discovery"},{"key":"10.1016\/j.bmc.2017.08.020_h0165","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1161\/CIRCGENETICS.115.001219","article-title":"Finding the therapeutic sweet spot: using naturally occurring human variants to inform drug design","volume":"8","author":"Burnet","year":"2015","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.bmc.2017.08.020_b0150","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.drudis.2009.07.014","article-title":"The impact of aromatic ring on compound developability \u2013 are too many aromatic rings a liability in drug design?","volume":"14","author":"Ritchie","year":"2009","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.bmc.2017.08.020_b0155","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/10629360802083855","article-title":"Prediction of drug solubility from molecular structure using a drug-like training set","volume":"19","author":"Huuskonen","year":"2008","journal-title":"SAR QSAR Environ Res"},{"key":"10.1016\/j.bmc.2017.08.020_b0160","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1128\/AAC.02733-13","article-title":"Switch-loop flexibility affects transport of large drugs by the promiscuous AcrB multidrug efflux transporter","volume":"58","author":"Cha","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2017.08.020_b0165","doi-asserted-by":"crossref","first-page":"6037","DOI":"10.1016\/j.tetlet.2010.09.044","volume":"51","author":"Todorovic","year":"2010","journal-title":"Tetrahedron Lett"},{"key":"10.1016\/j.bmc.2017.08.020_b0170","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1016\/j.bmcl.2007.07.068","volume":"18","author":"Harriman","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2017.08.020_b0175","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1021\/ci00063a006","volume":"29","author":"Viswanadhan","year":"1989","journal-title":"J Chem Inf Comput Sci"},{"key":"10.1016\/j.bmc.2017.08.020_b0180","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/mrc.1260310116","article-title":"Ab initio IGLO study of the syn\/anti dependence of the 13C NMR chemical shift in simple amides","volume":"31","author":"Jiao","year":"1992","journal-title":"Magn Reson Chem"},{"key":"10.1016\/j.bmc.2017.08.020_b0185","doi-asserted-by":"crossref","first-page":"e33867","DOI":"10.1371\/journal.pone.0033867","article-title":"Inhibition of ERb induces resistance to cisplatin by enhancing Rad51\u2013mediated DNA repair in human medulloblastoma cell lines","volume":"7","author":"Wilk","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bmc.2017.08.020_b0190","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/1476-4598-9-159","article-title":"Research ROS accumulation and IGF-IR inhibition contribute to fenofibrate\/PPAR\u03b1-mediated inhibition of Glioma cell motility in vitro","volume":"9","author":"Drukala","year":"2010","journal-title":"Mol Cancer"}],"container-title":["Bioorganic &amp; Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089617316206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089617316206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:50:43Z","timestamp":1760835043000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089617316206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":42,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0968089617316206"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2017.08.020","relation":{},"ISSN":["0968-0896"],"issn-type":[{"type":"print","value":"0968-0896"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticancer potential of aminomethylidene-diazinanes I. Synthesis of arylaminomethylidene of diazinetriones and its cytotoxic effects tested in glioblastoma cells","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2017.08.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}